Additionally, the study showed that patients receiving intracoronary CD34+ stem cell therapy had a greater reduction in AF at 3 months (–14.6 ± 4.8 vs. –4.5 ± 0.3 episodes, p < 0.01) and 6 months (–15.6 ± 4.0 vs. –3.0 ± 1.2 events, p < 0.01) compared to placebo. This evidence concerns the gene CD34 and atrial fibrillation.